IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism
Open accessPublished version of a preprint
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Oncogenic mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) occur in several types of cancer, but the metabolic consequences of these genetic changes are not fully understood. In this study, we performed 13C metabolic flux analysis on a panel of isogenic cell lines containing heterozygous IDH1/2 mutations. We observed that under hypoxic conditions, IDH1-mutant cells exhibited increased oxidative tricarboxylic acid metabolism along with decreased reductive glutamine metabolism, but not IDH2-mutant cells. However, selective inhibition of mutant IDH1 enzyme function could not reverse the defect in reductive carboxylation activity. Furthermore, this metabolic reprogramming increased the sensitivity of IDH1-mutant cells to hypoxia or electron transport chain inhibition in vitro. Lastly, IDH1-mutant cells also grew poorly as subcutaneous xenografts within a hypoxic in vivo microenvironment. Together, our results suggest therapeutic opportunities to exploit the metabolic vulnerabilities specific to IDH1 mutation. Cancer Res; 74(12); 3317–31. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“one likely role is as an inflammatory signal, acting via SUCNR14,5,161,162.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [161]
Experimental — accuracy not yet measuredIn the citing paper
“For example, tumors harboring an IDH mutation have increased sensitivity to hypomethylating agents (Turcan et al., 2013), electron transport chain inhibitors (Grassian et al., 2014), depletion of the coenzyme NAD+ (Tateishi et al., 2015) and chemoradiotherapy (Cairncross et al., 2014).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Grassian et al., 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“Pharmacologic profiling of the CCLE was performed as previously described (32).”
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 1×
“4 Introduction Mutations in the metabolic enzymes isocitrate dehydrogenase 1 and 2 (IDH1/2) have been identified in a variety of tumor types, including acute myeloid leukemia (AML), gliomas, cholangiocarcinomas, and chondrosarcomas (1-9).”
Self-citationIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 2×
“Numerous reports have linked 2-HG accumulation to epigenetic changes, which are thought to contribute to alterations in cellular differentiation status (13-22).”
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662 · cited 1×
“The metabolic deficiencies of IDH1-mutant cells occur at oxygen tensions that are likely to occur in solid tumors and some normal tissues (44).”
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · cited 1×
“4 Introduction Mutations in the metabolic enzymes isocitrate dehydrogenase 1 and 2 (IDH1/2) have been identified in a variety of tumor types, including acute myeloid leukemia (AML), gliomas, cholangiocarcinomas, and chondrosarcomas (1-9).”
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020 · cited 2×
“2-HG is not typically present at high levels in normal cells but accumulates considerably in cells with IDH1/2 mutations as well as in the tumors of patients with IDH1/2 mutations, and has thus been termed an “oncometabolite” (10-12).”
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985 · cited 2×
“Numerous reports have linked 2-HG accumulation to epigenetic changes, which are thought to contribute to alterations in cellular differentiation status (13-22).”
Cited by
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
“Mutation of isocitrate dehydrogenase-1 (IDH-1) is an important topic in cancer metabolism, and there is preclinical evidence justifying study of the combination of a biguanide and inhibitors of mutated IDH-1 (Grassian et al., 2014).”
BackgroundAcetyl coenzyme A: a central metabolite and second messenger
Pietrocola, F., Galluzzi, L., Bravo-San Pedro, J. M., Madeo, F., & Kroemer, G. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.014 · Cited by 1,378
“Of note, glutamate also can be converted into a-ketoglutarate by GLUD1, a cytosolic variant of GLUD2, at least in some settings (Grassian et al., 2014).”
BackgroundTargeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
“For example, tumors harboring an IDH mutation have increased sensitivity to hypomethylating agents (Turcan et al., 2013), electron transport chain inhibitors (Grassian et al., 2014), depletion of the coenzyme NAD+ (Tateishi et al., 2015) and chemoradiotherapy (Cairncross et al., 2014).”
BackgroundHypoxia and Metabolic Adaptation of Cancer Cells
Eales, K. L., Hollinshead, K. E. R., & Tennant, D. A. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.50 · Cited by 724
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Han, S., Liu, Y., Cai, S. J., Qian, M., Ding, J., Larion, M., Gilbert, M. R., & Yang, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0814-x · Cited by 657
Metadata
- Authors
- Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., Joud-Caldwell, C., Chung, F., Yin, H., Handly, E. D., Straub, C., Growney, J. D., Vander Heiden, M. G., Murphy, A. N., Pagliarini, R., & Metallo, C. M.
- Affiliations
- University of California San Diego (US)
- Authors' Affiliations: 1Novartis Institutes for Biomedical Research; 2Koch Institute for Cancer Research, 3Massachusetts Institute of Technology, Cambridge, Massachusetts; Departments of 4Bioengineering and 5Pharmacology; and 6Moores Cancer Center, University of California, San Diego, La Jolla, California
- Corresponding author
- Pagliarini, Raymond
- Metallo, Christian M.
- ORCID
- Venue
- Cancer Research
- Published
- 2014-06-12
- Volume
- 74
- Issue
- 12
- Pages
- 3317-3331
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4885639
- OpenAlex
- W2155800445
- Cited by
- 280
- References
- 52
- Citations by year
- 2026: 9 · 2025: 27 · 2024: 23 · 2023: 22 · 2022: 30 · 2021: 25 · 2020: 31 · 2019: 27 · 2018: 17 · 2017: 28 · 2016: 18 · 2015: 18 · 2014: 5
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- PMC
- Funders
- Wellcome Trust
- National Cancer Institute (R01CA168653, R01CA188652, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- IDH1 mutation, IDH2 mutation, TCA cycle, oxidative metabolism, mitochondrial metabolism, reductive carboxylation, hypoxia, electron transport inhibition, metabolic reprogramming, cancer metabolism, metabolic vulnerability, isogenic cell lines, xenograft tumor growth
- MeSH terms
- Animals, Antineoplastic Agents, Citric Acid Cycle, Enzyme Inhibitors, Glutamine, Humans, Isocitrate Dehydrogenase, Mitochondria, Oxidation-Reduction, Stress, Physiological, Cell Hypoxia, Mutation, Missense, Xenograft Model Antitumor Assays, HCT116 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-0772-t
- The paper
- Grassian, A. R., Parker, S. J., Davidson, S. M., Divakaruni, A. S., Green, C. R., Zhang, X., Slocum, K. L., Pu, M., Lin, F., Vickers, C., Joud-Caldwell, C., Chung, F., Yin, H., Handly, E. D., Straub, C., Growney, J. D., Vander Heiden, M. G., Murphy, A. N., Pagliarini, R., & Metallo, C. M. (2014). IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-0772-t
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.